Cronos Group (TSE:CRON) Price Target Cut to C$12.00 by Analysts at Canaccord Genuity
Cronos Group (TSE:CRON) had its price objective decreased by Canaccord Genuity from C$13.00 to C$12.00 in a research report sent to investors on Wednesday, BayStreet.CA reports.
Several other research analysts also recently commented on the company. Cowen cut their target price on Cronos Group from C$21.00 to C$17.00 in a research note on Tuesday, September 3rd. Jefferies Financial Group cut their target price on Cronos Group from C$15.00 to C$10.00 in a research note on Friday, October 11th. BMO Capital Markets upgraded Cronos Group from an underperform rating to a market perform rating and set a C$16.00 target price for the company in a research note on Thursday, September 5th. Finally, CIBC cut their target price on Cronos Group from C$20.00 to C$17.00 in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of C$18.56.
TSE CRON traded down C$0.58 during trading hours on Wednesday, hitting C$9.03. The company had a trading volume of 1,090,621 shares, compared to its average volume of 1,472,147. Cronos Group has a 52 week low of C$8.82 and a 52 week high of C$32.95. The firm has a 50 day simple moving average of C$11.25 and a 200 day simple moving average of C$16.95. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.64 and a current ratio of 1.68. The firm has a market capitalization of $3.23 billion and a price-to-earnings ratio of 12.70.
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada.
See Also: What is a conference call?
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.